Clinical Trial Update: Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating cannabidiol for anxiety and depression in individuals with bipolar disorder and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Mclean Hospital | Conditions: Bipolar Disorder | Phase 2 | Status: RECRUITING